S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Integra LifeSciences Stock Forecast, Price & News

-2.60 (-3.85%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
157,232 shs
Average Volume
364,137 shs
Market Capitalization
$5.49 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Integra LifeSciences logo

About Integra LifeSciences

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.


Integra LifeSciences (NASDAQ:IART) Issues FY 2021 Earnings Guidance
November 9, 2021 |  americanbankingnews.com
Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.37 billion
Cash Flow
$4.02 per share
Book Value
$19.26 per share


Net Income
$133.89 million
Pretax Margin




Free Float
Market Cap
$5.49 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.02 out of 5 stars

Medical Sector

591st out of 1,391 stocks

Surgical & Medical Instruments Industry

60th out of 125 stocks

Analyst Opinion: 2.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

Is Integra LifeSciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view top-rated stocks.

How has Integra LifeSciences' stock price been impacted by Coronavirus (COVID-19)?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IART stock has increased by 40.8% and is now trading at $64.86.
View which stocks have been most impacted by COVID-19

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Integra LifeSciences

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) announced its quarterly earnings results on Monday, November, 1st. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.14. The life sciences company earned $386.86 million during the quarter, compared to the consensus estimate of $384.47 million. Integra LifeSciences had a trailing twelve-month return on equity of 17.33% and a net margin of 14.19%. The company's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.80 earnings per share.
View Integra LifeSciences' earnings history

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of $3.160-$3.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.020. The company issued revenue guidance of $1.54 billion-$1.55 billion, compared to the consensus revenue estimate of $1.54 billion.

What price target have analysts set for IART?

7 brokerages have issued twelve-month target prices for Integra LifeSciences' stock. Their forecasts range from $65.00 to $88.00. On average, they anticipate Integra LifeSciences' share price to reach $76.75 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price.
View analysts' price targets for Integra LifeSciences
or view top-rated stocks among Wall Street analysts.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:
  • Peter J. Arduini, President, Chief Executive Officer & Director
  • Glenn G. Coleman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • Carrie Anderson, Chief Financial Officer, Treasurer & Executive VP
  • William Compton, Chief Information Officer & Senior Vice President
  • Kenneth E. Burhop, Chief Scientific Officer & Vice President

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (9.74%), Janus Henderson Group PLC (4.89%), Eaton Vance Management (4.73%), Cooke & Bieler LP (2.81%), Alliancebernstein L.P. (2.48%) and Dimensional Fund Advisors LP (1.56%). Company insiders that own Integra LifeSciences stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences

Which institutional investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Janus Henderson Group PLC, Cooke & Bieler LP, Jennison Associates LLC, Eagle Asset Management Inc., Segall Bryant & Hamill LLC, Renaissance Technologies LLC, and Tudor Investment Corp Et Al. Company insiders that have sold Integra LifeSciences company stock in the last year include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences
or view top insider-selling stocks.

Which institutional investors are buying Integra LifeSciences stock?

IART stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Eaton Vance Management, Fuller & Thaler Asset Management Inc., Pura Vida Investments LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Nisa Investment Advisors LLC, and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Integra LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $64.86.

How much money does Integra LifeSciences make?

Integra LifeSciences has a market capitalization of $5.49 billion and generates $1.37 billion in revenue each year. The life sciences company earns $133.89 million in net income (profit) each year or $2.54 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,700 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is www.integralife.com.

Where are Integra LifeSciences' headquarters?

Integra LifeSciences is headquartered at 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at (609) 275-0500, via email at [email protected], or via fax at 609-750-4277.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.